Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Cyclogenix is a UK biotechnology company whose founding background dates back to 2008. Its core focus is using cyclic peptide plant microprotein families, phage display libraries, and antibody engineering technologies to support drug discovery, delivery, and disease-targeting research. Based on the collected content, it looks more like a CRO/biotech R&D service provider than a standard SaaS or enterprise software platform.
The company offers four main service areas: human antibody discovery, VNAR antibody discovery, cyclic peptide discovery, and biotherapeutic delivery. Its human phage display antibody library contains more than 70 billion distinct fully human antibodies; its cyclic peptide “loop replacement” library includes over 50 billion unique clones. The VNAR area emphasizes small molecular size, solubility, and stability, making it suitable for exploring special binding characteristics. Its delivery work covers transmembrane delivery of drugs, peptides, and proteins, as well as BBB-related bioavailability research.
The website does not provide standard packages, pricing, payment methods, or trial information. It describes its offering as “customized services for each project,” including the creation of project plans and screening strategies, with an experienced team assigned to deliver results within an agreed timeframe. Therefore, procurement should mainly be handled through project-based commercial discussions, rather than evaluated like a conventional SaaS subscription.
Its strengths lie in a clear technical approach covering antibody libraries, single-domain antibodies, cyclic peptides, and delivery systems, along with disclosure of large-scale molecular library resources. Team members have experience in protein engineering, display technologies, and diagnostic research. The limitations are also clear: the website does not disclose quality systems, data security measures, compliance certifications, customer case studies, project pricing, or detailed delivery workflows. Nor does it show enterprise software capabilities such as APIs, third-party integrations, online collaboration, permission management, or cloud/self-hosted deployment.
It is better suited to pharmaceutical companies, biotech companies, university translational teams, or preclinical R&D teams for antibody/peptide screening, custom molecular tools, BBB delivery, oral delivery, or tumor multispecificity-related exploration. It is not suitable as a general SaaS procurement target.
The main content does not provide information on access from China, nodes, or local services, so the actual access status is unknown.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on cyclogenix.com official site.
cyclogenix.com is an United Kingdom Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach cyclogenix.com directly.